TNF Antibody Development Service

TNF antibodies have shown great promise for the therapeutics of various diseases of immune system. Our company provides full-scale research services to help you develop highly specific antibodies of TNF proteins and accelerate the therapeutic antibodies development in Autoimmune Diseases & Inflammation.

TNF in Autoimmune Diseases & Inflammation

The TNF family mainly consists of TNF-α and TNF-β, both of which are pleiotropic cytokines playing important roles in inflammation. The mechanism of the TNF proteins in Autoimmune Diseases & Inflammation has not been fully understood. Inhibition of TNF by neutralizing antibodies has been proved to be a pivotal strategy to alleviate the inflammatory response. This promising therapeutics modality has attracted investment from pharmaceutical companies, as at least five monoclonal antibodies targeting TNF have been approved for the therapeutics of multiple Autoimmune Diseases & Inflammation.

Fig.1 Summary of anti-TNF impact on T cells in rheumatoid arthritis and possible topics of interest for future investigations. (Davignon J., et al., 2018)

• TNF-α
  The ubiquitously expressed TNF-α exerts its biological function by binding two transmembrane receptors, TNFR1 and TNFR2. TNF-α activates TNFR1 to trigger distinct signaling pathways, including the activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinases (MAPKs), to induce cytotoxicity-dependent apoptosis and proinflammatory response. When TNF-α functions through TNFR2, its downstream NF-κB, MAPKs and AKT signaling pathways are activated in order to regulate the cell survival, proliferation and migration. Ectopic expression of TNF-α activates and recruits inflammatory cytokines to causes cell injury, suggesting the great significance of interfering the activity to inhibit excessive inflammatory response.

• TNF-β
  >TNF-β predominantly expressed in activated T and B cells balances the suppression and enhancement of adaptive immune responses through different pathways. With TNF-β at a low level, the expression of IL-23 is diminished to relieve the repression of Foxp3, leading to the transformation of cells to a Treg identity, as well as the inhibition of Th1, Th2, and CD8+ T cells, thus resulting in the suppression of the immune reaction. High levels of TNF-β, together with IL-6 and IL-21, stimulate the expression of the IL-23 receptor, which in turn enables the transition of Th17 cells and the release of pro-inflammatory cytokines, leading to the activation of immune response. Therefore, inhibition of TGF-β or TGF-β signaling combined with the appropriate cytokine milieu is a promising strategy for the therapeutics of Autoimmune Diseases & Inflammation.

Our Services

Therapeutic antibodies of TNF proteins are revolutionized therapy for Autoimmune Diseases & Inflammation. Our company provides mature package of antibodies development services for TNF signaling pathways as the following workflow:

Antigen Validation

TNF signaling pathways

Antibody Generation

Antibody Optimization

Antibody Characterization

Antibody Production & Purification

Our advantages

With expertise from immunology and cell engineering biology, and participating of researchers with experience in successful antibody development from a large number of practices, our company is committed to providing meticulous services for the development of therapeutic antibodies for TNF signaling pathways. If you are interested in our services, please contact us for more detailed information.

Reference

1. Davignon, Jean-Luc et al. “Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.” Arthritis research & therapy 20,1 (2018): 229.